“Point of Care” T cell therapy
Adheren’s ACC™ process requires only one hour from start to finish. The process of T cell isolation, modification, and infusion can be done using a single machine, thus eliminating the need of T cell engineering and expansion. ACC is highly beneficial to patients by significantly reducing the time and cost of T cell therapy.
Compatible with existing antibodies
The Antibody Cell Conjugation (ACC™) platform is readily available today for application to existing antibodies, transforming antibody therapy to T cell immunotherapy, and significantly reducing research and development time and cost.
No genetic engineering of T cells
ACE-T does not require genetic engineering of T cells and viral transduction, greatly increasing the safety profile of the technology, and decreasing the manufacturing time and cost. Thus, delivering a rapid and safe treatment option for cancer patients.